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Background: Neuroblastoma is the most common extracranial malignant solid tumor 
in children under 5 years, and it is characterized by wide clinical and biological hetero-
geneity. N-myc oncogene amplification is considered to be one of the most important 
prognostic factors used to evaluate survival in these patients. 
Objectives: The aim of our study was to determine amplification of the N-myc oncogene 
using real-time quantitative polymerase chain reaction (PCR) and to show the influence 
of N-myc amplified tumors on the overall survival rate.
Patients and Methods: This study is an analytical historical cohort study of forty chil-
dren with neuroblastoma admitted to the Shafa Hospital, Iran from 1999 to 2010. Par-
affined blocks of tumoral tissue were analyzed for N-myc amplification by a PCR. The 
degree of N-myc amplification was derived from the ratio of the N-myc oncogene and 
the single copy reference gene, NAGK. In the statistical analysis, a Kaplan-Meier survival 
analysis was used.
Results: We found a variable degree of N-myc amplification, from 3 to 2 200, in 32 of 
the 40 neuroblastomas (80%). NMYC amplification was seen more frequently in patients 
older than 2.5 years (71.9%), stage 4 (65.6%) and female (53.1%). Median survival time in the 
males was significantly longer than in the females (P = 0.03). The overall median survival 
for N-myc amplified tumor patients was 20 months, and 30 months for the non ampli-
fied tumors.
Conclusions: The N-myc amplified tumors may increase the probability of more aggres-
sive behavior and rapid tumor progression, especially in advanced stages of neuroblas-
toma. This study confirmed the importance of obtaining correct measurements of on-
cogene amplification in the early evaluation of neuroblastomas in order to target more 
aggressive therapies in patients with a higher risk of cancer progression.
 Implication for health policy/practice/research/medical education:
Determining N-myc amplification helps us to: 1, Better prognostic and risk stratification; 2, Choosing the appropriate chemotherapy.
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1. Background
Neuroblastoma is the most common extracranial solid 
tumor in children younger than 5 years (1) and it is a lead-
ing cause of death due to the development of malignancy 
in this population. Because of the extent of the disease at 
diagnosis, prognosis is generally poor in most patients 
(2). However, this malignancy can also exhibit favorable 
characteristics, including the possibility of evolving into 
a more benign form, or regressing spontaneously (2). 
Clinical evaluation of the disease, including in vivo im-
aging and bone marrow examination, and the age of the 
patient at diagnosis allows a definitive prognosis to be 
made in the majority of cases (3).
Progress in the management of neuroblastoma re-
quires precise evaluation, and this is based on the char-
acterization of a number of biochemical and molecular 
abnormalities (4). Molecular characterization of neuro-
blastoma could be a better tool in the diagnosis of tumor 
aggressiveness and progression. There are several molec-
ular markers which have been variously related to patient 
survival; deletion of the short arm of chromosome 1 (5), 
DNA ploidy (6), and the expression of nerve growth factor 
receptor, encoded by the TRKA gene (7). However, in clini-
cal practice, MYCN amplification has routinely been used 
to determine diagnosis as a basis molecular marker (2, 5). 
MYCN amplification seems to correlate with biological 
features such as, advanced disease stage and rapid tumor 
progression of neuroblastoma (8, 9). 
Oncogene amplification is a common DNA alteration 
in neuroblastoma, causing an increase in encoded pro-
tein synthesis (10). Several methods have been suggested 
to determine oncogene amplification, based mainly on; 
Southern or dot blot methods (11, 12), quantitative poly-
merase chain reaction (PCR) (13, 14), and fluorescence in 
situ hybridization techniques (15). The PCR is a relatively 
rapid and simple method. PCR has many benefits over 
conventional methods for detecting gene amplification; 
it does not require radio-labeled probes and requires less 
DNA samples. Such diagnostic technique benefits are of 
special interest in small tumor samples which have been 
obtained by bone marrow aspiration or fine needle aspi-
ration (16). 
Shafa Medical, Educational and Research Center is a 
major referral hematology and oncology hospital in the 
southwest of Iran and many children with neuroblasto-
ma have been managed in this center. To the best of our 
knowledge, no study has been performed to investigate 
the effect of N-myc amplification on median survival 
rates in children with neuroblastoma.
2. Objectives
Therefore, we conducted a study to determine N-myc 
amplification in children with neuroblastoma using 
standard polymerase chain reaction (PCR) and to show 
the impact of its amplification on patients’ median sur-
vival.
3. Patients and Methods
This study is an analytical historical cohort research. All 
of the children with a primary diagnosis of neuroblas-
toma admitted to the Shafa Hospital from April 1999 to 
April 2010, and where their paraffin embedded samples 
were also available, entered the study. In each case docu-
mentation was made of the following; demographic indi-
cators, stage of tumors and whether the patient was alive 
or dead. Forty patients were included in this study. There 
were 22 (55%) males and 18 (45%) females. The age of the 
patients ranged from 6 months to 11 years; 12 patients ≤ 
2.5 years of age and 28 were > 2.5 years. Patients staging 
were performed according to the International Neuro-
blastoma Staging System (INSS). Of the 40 patients, one 
(2.5%) was in stage II of the disease, 10 (25%) were in stage 
III, 27 (67.5%) were in stage IV and two (5%) were in stage 
IV-s (Table 1).
In the first step, paraffin-embedded tissue sections were 
cut and then the paraffin was dissolved in xylene. After 
precipitation of the sample and removal of the superna-
tant, the residual xylene was removed by washing with 
ethanol. In the next step, the DNA was extracted. For as-
surance about the quality of the extracted DNA, both pu-
rity and concentration were measured. “High Pure PCR 
template preparation kit; Roche Diagnostics Corpora-
tion” was selected for chemical/enzymatic analysis of cell 
lysis, and nuclease inactivation, while adsorption chro-
matography was used for nucleic acid purification. The 
kit contains 5 different buffers, proteinase K, high pure 
tubes with pre-packed silica filters and collection tubes. 
In brief, the starting material is lysed by incubation with 
lysis buffer and proteinase K to break open cell mem-
branes and expose DNA and RNA. Binding buffer is added 
to inactivate the nucleases and the solution is transferred 
into filter tubes and centrifuged for 2 minutes. After three 
washes with different buffers, the nucleic acid bound to 
the glass fiber filter was purified and could be eluted with 
the elution buffer into a sterile 1.5 micro centrifuge tube. 
The Eppendorf BioPhotometer (Eppendorf, Hamburg, 
Germany) is the best instrument for quick and routine 
measurements of the optical density of samples at pre-
defined wavelengths. With this device, we estimated the 
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concentration of the extracted DNA. DNA concentration 
can be determined by measuring the absorbance at 260 
nm (A260) in a spectrophotometer. The ratio of the read-
ings at 260 nm and 280 nm (A260/ A280) provides an es-
timate of DNA purity with respect to contaminants that 
absorb UV light, such as proteins. The fragmentation 
of purified nucleic acid was checked using denaturing 
agarose gel electrophoresis. Quantitative PCR were per-
formed in the Corbett Rotor-Gene 6000 (Corbett Life Sci-
ence) in a 25 µL final volume. The PCR mixture contained 
2.5 µL 10x buffer, 1.5 µmol MgCL2, 20 nmol/L of each prim-
er, 10 nmol/L of each probe, 1 unit of Taq DNA and 100 ng 
of extracted DNA. 
Both genes (NAGK gene and MYCN oncogene) were am-
plified for 120 seconds at 95° C in the first step, followed 
by 45 cycles of 30 seconds at 95° C, 30 seconds at 60° C, 
and 30 seconds at 72° C. The degree of amplification for 
each sample was derived from the ratio of the number of 
molecules of MYCN to the number of molecules of NAGK 
reference gene. Only samples in which the MYCN/NAGK 
ratio was three or more were considered as amplified for 
this oncogene. Statistical analysis was performed by the 
Kaplan-Meier method (22).
4. Results
N-myc amplification was detected in 32/40 (80%) of 
the patients. The N-myc/NAGK ratio of the 32 amplified 
samples varied from 3 to 2 200. Of these 32 patients with 
N-myc amplifications 9 (28.1%) were ≤ 2.5 years of age, 16 
(50%) were 2.6 - 5 years of age and 7 (21.9%) were > 5 years 
of age (Table 2). Fifteen of these 32 (46.9%) patients were 
males, while 17/32 (53.1%) of the patients were female. Nine 
of the 32 (28.1%) were in stage III, 21 (65.6%) were in stage 
IV, the remaining 2 (6.2%) were stages II and IV-s tumors. 
Ninety percent of stage III and 77.8% of stage IV tumors in-
cluded in the study had N-myc amplification. In children 
≤ 2.5 years of age, the incidence of N-myc amplification 
was 30% in stage III tumors and 14.8% in stage IV tumors. 
In children > 2.5 years of age, the incidence of N-myc am-
plification was 60% in stage III tumors and 62.9% in stage 
IV tumors. As shown in Table 2, with increasing age and 
stage of the tumor N-myc amplification increased.
Patients’ charts showed that all of the children had died 
within 36 months after diagnosis. In the male’s survival 
rate, a comparison of patients with and without N-myc 
amplification had no statistically significant difference in 
this study. However, in the females, N-myc amplification 
had a significant negative impact on patients’ survival in 
comparison with females without N-myc amplification 
(P < 0.02). In females with N-myc amplification all of the 
patients had died within 24 months following diagnosis. 
(Figures 1 & 2). Overall patient median survival was longer 
in males either with or without N-myc amplification in 
comparison with females (P < 0.03). 
We have also taken into account the effect of N-myc 
amplification and stage of the malignancy on survival. 
Survival of the patients at stages 3 and 4 showed no dif-
ference between patients with or without N-myc ampli-
fication (Figures 3 & 4).
5. Discussion
The measurement of MYCN gene amplification in neu-
roblastoma is one of the most important clinical appli-
cations of oncogene amplification detection in oncology. 
Both prognosis and treatment of this tumor are deeply 
influenced by this molecular marker (2, 5, 17-21). Any im-
provement in the accuracy and reliability in the deter-
mination of MYCN amplification could represent an im-
portant tool in the management of this malignancy. Our 
data demonstrated that the measurement of MYCN am-
plification with a TaqMan reaction is easy, rapid, precise, 
and accurate. Our results confirmed the high incidence 






Table 1. Stage of Neuroblastoma in the Patients
Stage                                                                      Age, y, No. (%)
              Patients ≤ 2.5 years, n=12                  Patients > 2.5 years, n = 28
Amplified Not amplified Amplified Not amplified
2 1 (8.33) 0 0 0
3 3 (25) 0 6 (21.4) 1 (3.5)
4 4 (33.3) 2 (16.6) 17 (60.7) 4 (14.2)
4s 1 (8.33) 1 (8.33) 0 0
in age group 9 (75) 3 (25) 23 (82.1) 5 (17.8)
Total 9 (22.5) 3 (7.5) 23 (57.5) 5 (12.5)
Table 2.  Amplification of N-myc in Different Stages of Neuroblastoma Based on the Age of Patients
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found oncogene amplification in 80% of the patients, 
with a major incidence in advanced tumor stages (2). 
Previous studies have showed the effect of gender, 
stage, and N-myc amplification on median survival rates 
in patients with neuroblastoma. Our results showed that 
survival was no different in males with or without N-myc 
amplification, however, females without N-myc amplifi-
cation had longer survivals compared with females who 
had N-myc amplification. Concerning the reasons for this 
finding we are not clear, but gender seems to be a more 
important prognostic factor than N-myc amplification 
in median survival rates of patients with neuroblastoma. 
Our results also suggest that N-myc amplification has a 
significant impact on median survival in females with 
neuroblastoma. Moreover, our results indicate that male 
children had greater resistance to the effects of N-myc 
amplification.
The results of our study are in accord with previous 
studies. In a study that was conducted in Italy, 49 chil-
dren with neuroblastoma were investigated for N-myc 
amplification and were divided into three groups; group 
A (n = 23) included patients with no MYCN amplification, 
group B (n = 22) included patients with low amplification 
(between 2 and 8), and group C (n = 4) included patients 
with high amplification (≥ 9). The analysis of cumulative 
survival by Kaplan-Meier curves showed that patients 
with MYCN amplification had a significantly worse prog-
nosis, compared with patients in whom the oncogene 
was not amplified (22).
Our results should be interpreted in the face of certain 
limitations. Our work was a retrospective cross-sectional 
study with only a small sample size, thus designing larg-
er and longer term prospective studies on this subject 
are recommended. Also, we did not consider degrees of 
N-myc amplification on patient median survival and pa-
tients were only divided into two groups, with and with-
out N-myc amplification. 
In conclusion, the prognostic value of MYCN amplifica-
tion in neuroblastoma is confirmed from our data. The 
analysis of cumulative survival curves confirmed that the 
prognosis is worse in patients with MYCN amplification. 
Figure 1. Kaplan-Meier Survival Curve for Males
Figure 2. Kaplan-Meier Survival Curve for Females
Figure 3. Kaplan-Meier Survival Curve in Patients With N-myc Amplifica-
tion Based on the Stage of the Tumor
Figure 4. Kaplan-Meier Survival Curve in Patients Without N-myc Ampli-
fication Based on the Stage of the Tumor
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These data also validate the importance of correct mea-
surement of oncogene amplification in the clinical evalu-
ation of neuroblastomas to direct more aggressive thera-
pies in patients with a higher risk of cancer progression. 
However, to obtain clear evidence of the possible clinical 
impact of a TaqMan assay for MYCN amplification mea-
surement, larger groups of patients need to be studied.
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